Mandate

Vinge advised Sapa on Chinese railways agreement

April 28, 2011

Vinge in Hong Kong has advised Sapa (a wholly owned subsidiary of the Norwegian Orkla ASA) in conjunction with the entry into an agreement with China's largest aluminum company, Chalco, concerning the supply of aluminum profiles to the Chinese railway industry. The joint venture agreement was executed in April this year at a cermony in Beijing attended by 70 specially invited guests. Each party holds 50% of the shares in the joint venture company. In total, the deal relates to an investment of approximately EUR 70 million. The joint venture agreement entails, among other things, that Sapa will be involved in the development of high speed trains for the Chinese market. The agreement has attracted a great deal of interest in both China and Norway.

Vinge's team consisted of Katarina Nilsson, the head of Vinge's China operations.

Related

Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of MedMera Bank AB

Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of all shares in MedMera Bank AB from Kooperativa Förbundet for a total consideration of SEK 1,960 million. The transaction positions Morrow Bank as a leading Nordic platform in consumer finance with combined gross loans of SEK 28.2 billion.
March 24, 2026

Vinge advises NEWS, a portfolio company of Litorina, in connection with the sale of Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG

Vinge advises Northern Environmental and Water Solutions AB (“NEWS”), a portfolio company of Litorina, in connection with the sale of the operating subsidiaries Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG (Vienna Stock Exchange: WIE). The transaction is expected to be completed in Q2 2026.
March 24, 2026

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026